Mesoblast: Mesoblast Added to S&P/ASX 200 INDEX
March 06, 2025 18:54 ET | Source: Mesoblast Limited NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) - Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its addition to the S&P Dow Jones Indices' S&P/ASX 200 Index effective March 6, 2025 on the Australian Stock Exchange (ASX). The S&P/ASX [...]
Read full article »
Mesoblast is an Australia-based regenerative medicine company that develops allogeneic cellular medicines for the treatment of inflammatory and cardiovascular diseases.
Read more